MBX Biosciences, Inc. (MBX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $39.30: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.50; Below-average business quality.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone... Read more
Sell if holding. Engine safety override at $39.30: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.50; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 70, MACD bullish. Score 5.6/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — MBX Biosciences, Inc.
Latest news
- NEWS MBX Biosciences Highlights Sustained Calcium Control In Rare Disease — benzinga Jun 12, 2026 positive
- NEWS 12 Health Care Stocks Moving In Friday's Pre-Market Session — benzinga Jun 12, 2026 neutral
- NEWS Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session — benzinga Jun 12, 2026 neutral
- NEWS MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once — benzinga Jun 12, 2026 positive
- NEWS Earnings Scheduled For May 14, 2026 — benzinga May 14, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $39.30: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.50; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 70, MACD bullish. Prior stop was $36.36. Score 5.6/10, moderate confidence.
Take-profit target: $60.11 (+53.7% upside). Prior stop was $36.36. Stop-loss: $36.36.
Quality below floor (1.6 < 4.0).
MBX Biosciences, Inc. trades at a P/E of N/A (forward -9.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover MBX with a consensus score of 4.1/5. Average price target: $69.
What does MBX Biosciences, Inc. do?MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of...
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.